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Background. Most patients with metastatic prostate cancer are endocrinologically treated with LHRH agonist, but ﬁnally
castration-refractory and hormone-refractory cancers occur. Serum testosterone levels get low to “the castration level” by LHRH
agonists but may not get low enough against castration-refractory prostate cancer. Methods. As case series, twelve patients
suﬀering from hormone-refractory prostate cancer continuously on LHRH agonist underwent surgical castration. Additionally,
one hundred and thirty-nine prostate cancer patients on LHRH agonist or surgical castration were tested for serum total
testosterone levels. Results. Surgical castration caused decrease in serum PSA in one out of 12 hormone-refractory prostate cancer
patients with PSA reduction rate 74%. Serum total testosterone levels were below the sensitivity threshold (0.05ng/mL) in 40 of
89 (44.9%) medically castrated patients and 33 of 50 (66.0%) surgically castrated patients (P = .20). Conclusion.E v e nh o r m o n e -
refractory prostate cancer patients are candidates for surgical castration because of endocrinological, oncological,and economical
reasons.
1.Background
Prostate cancer is the most prevalent cancer and the second
ranked malignancy which causes death among males in the
United States. In Japan as well, the prevalence and death
rate of prostate cancer is recently increasing (http://ganjoh
.ncc.go.jp/pro/statistics/gdb trend.html?1). Organ conﬁned
and minimally invasive prostate cancer can be treated
with local therapy such as radical prostatectomy, external
beam radiation, and brachytherapy with excellent prognosis.
Cryotherapy and high-intensity focused ultrasound for the
treatmentoflocalizedprostatecancerarealsoundervigorous
investigation with promising initial results. On the contrary,
metastatic prostate cancer is usually treated primarily with
androgen deprivation therapy with or without antiandro-
gens, leadingto goodto fair cancercontrol, butﬁnally result-
ing in hormone-refractory cancer, cancerrelapse, and cancer
death. By deﬁnition, castration-refractory prostate cancer
responds to secondary hormonal manipulations, including
antiandrogen withdrawal, estrogens, and corticosteroids,
while true hormone-refractory prostate cancer is resistant to
all hormonal measures (Guidelinesonprostate cancer, Euro-
pean Association of Urology 2010: http://www.uroweb.org/
gls/pdf/Prostate%20Cancer%202010%20June%2017th.pdf).
Androgendeprivationtherapy to benignprostatic hyper-
trophy was ﬁrst reported by White in1895[1]. In1941,Hug-
gins and Hodges successfully applied androgen deprivation
therapy to metastatic prostate cancer patients in the form of
surgical castration [2]. In the early 1980s, LHRH agonists
were introduced [3] in the endocrinological treatment of
advanced prostate cancer, and the oncological outcomes of
surgical castration by bilateral orchidectomy and medical
castration by LHRH agonists are now generally regarded as
the similar. Nevertheless, there are reports indicating that
LHRH agonists fail to achieve castrate levels of testosterone
[4–6]. According to a nonsystematic review of the literature,2 Advances in Urology
castration level of less than 0.5ng/mL was yielded in 95–
98.8% by leuprolide, and that less than 0.2ng/mL was in 87–
92% by leuprolide and in 96% by goserelin [7]. Generally
accepted deﬁnition of the cut-oﬀ point of castration level
0.5ng/mL was determined by the lower detection limit of
assay methods developed in the late 1960s and early 1970s
[8] but not used anymore. Despite advances in methodology
with more accurate lower limits of detection, the deﬁnition
of testosterone levels after bilateral orchiectomy, that is,
castration level, has not been updated so far. Moreover,
there have been no controlled trials which show that the
cancer-speciﬁc survival of the patients achieving testosterone
level less than 0.2ng/mL or less than 0.05ng/mL were more
favorable compared with those having testosterone level
between 0.2 and 0.5ng/mL.
Olapade-Olaopa et al. presented two cases of prostate
cancer who were compliant but resistant to LHRH ago-
nist therapy with normal testosterone levels, while they
responded to following surgical castration resulting in low
testosterone levels and clinical improvement as well as
decrease in PSA [9]. Those cases showed cluster of Leydig
cells in the excised atrophic testes. One reason why prostate
cancer is resistant to LHRH agonists may be because they
occasionally fail to castrate patients suﬃciently by unknown
reasons in the hypothalamo-pituitary-gonadal axis. Another
possibility isthattestosteronelevelsgetlowto “thecastration
level”by LHRH agonists but may not get low enough against
castration-refractory prostate cancer, as an upregulation of
androgen receptor in prostate cancer, and changes in the
signal transduction pathwaysdownstream ofthe receptorget
to utilize even little amount of testosterone. Thus, surgical
castration can completely eliminate remnant testosterone
produced by the testes then may have a possibility in selected
casestocontrolPSAandclinicalsymptomsofprostatecancer
which has been already treated with LHRH agonists.
Here we show the changes in serum testosterone levels
and PSA of hormone-refractory prostate cancer patients
who had been treated with LHRH agonists and were
surgically castrated. Additionally, we have assessed serum
testosterone levels of prostate cancer patients continuously
on androgen deprivation treatments, LHRH agonist, and
surgical castration, irrespective of their oncological status.
2.Methods
Twelve patients suﬀering from hormone-refractory prostate
cancer with multiple bone metastasis underwent surgical
castration under spinal or total anesthesia without leaving
testicular capsule between October, 2008 and August, 2010.
There were no complications associated with surgery. They
all were continuously on LHRH agonist, either leuprolide
or goserelin, until the time of surgery. All patients had
been given at least one antiandrogen (bicalutamide for all,
ﬂutamide for 8, chlormadinone acetate for 1), 9 given estra-
mustine, and 10 given corticosteroid during some periods.
Sevencaseshadbeenpreviouslytreatedwithdocetaxelbefore
surgical castration. Their clinical characteristics are listed
in Table 1. Serum PSA in all patients and total testosterone
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Figure 1: Serum testosterone levels in prostate cancer patients
continuously on LHRH agonist or surgical castration. Medical:
LHRH agonist, Surgical: surgical castration, vertical line: serum
testosterone level (ng/mL), horizontal line: time after induction of
LHRH agonist/surgicalcastration (years).
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Figure 2: PSA course of a hormone-refractory prostate cancer
patient whose PSA declined due to surgical castration.
￿:s u r -
gical castration, CMA: chlormadinone acetate, vertical line: PSA
(ng/mL), horizontal line: date. Before surgical castration, dose of
docetaxel every other week was 35mg/m2 per course.
in 8 patients were evaluated in pairs before and more
than one month after surgical castration. Excised testes in
every patient were histologically evaluated especially for the
existence of remnant Leydig cells using Hematoxylin-Eosin
staining by a board-qualifying pathologist.
One hundred and thirty-nine prostate cancer patients
on LHRH agonist (n = 89) or surgical castration (n =
50) at least for three months and patients who had never
experienced (n = 31) or who had quitted androgen dep-
rivation therapy (n = 10) were tested for their serum total
testosterone levels between August and October 2010, re-
gardless of their oncological status. In this study, serum
total testosterone was measured by the ECLIA assay (Elec-
trochemiluminescence Immunoassay), and the sensitivity
threshold oftotaltestosterone measurement was0.05ng/mL.Advances in Urology 3
Table 1
Case
No.
Age at
orchiectomy
Prebiopsy
PSA Biopsy GS LHRH agonist
administered
Duration of
LHRH agonist
PSA Testosterone Overall
survival pre- post- pre- post-
1 75 69 8 goserelin 3.9 4.9 2.9 0.10 0.05> 14.9
2 80 488 9 leuprolide 2.5 3.3 2.1 0.12 0.05> 10.6
3 90 10.7 9 goserelin 13.8 29.6 14.9 0.14 0.05> 17.5<
4 76 4.7 8 goserelin 7.0 9.6 16.6 0.11 0.05> 13.7<
5 67 315 8 leuprolide 1.6 924 553 0.07 0.51 9.6
6 77 1463 9 leuprolide 2.1 696 914 0.05> 0.05> 10.1
7 78 2.8 7 leuprolide 1.0 12 4.2 0.05> 0.05> 9.7<
8 78 107 8 goserelin 1.7 0.26 0.12 0.05> 0.05> 3.3<
9∗ 77 200 7 goserelin 10.3 187 48 0.07 NA 10.1
10 80 426 9 goserelin 0.9 34.1 53.7 NA 0.22 14.8
11 69 334 8 leuprolide 3.2 7.0 0.8 NA NA 26.1<
12 45 191 6 leuprolide 1.3 138 146 NA NA 4.4
UnitsofPSA:ng/mL,GS:Gleasonscore,durationofLHRHagonist:years,unitsofserumtestosterone:ng/mL,overallsurvival:survivalaftersurgicalcastration
(months), pre-: before surgical castration, post-: after surgical castration,
∗: a case where decrease in PSA was supposed to be due to surgical castration.
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Figure 3: PSA course after 2009/1/1 of the patient described in
Figure 2 is enlarged. After surgical castration, docetaxel (70mg/m2
per course every three weeks) was administered together with
zoledronic acid (4mg/body).
3.Results
PSA declined following surgical castration in 8 cases of
hormone-refractory prostate cancer patients on LHRH ago-
nist (Table 1), but only in one case PSA reduction was
supposed to be due to surgical castration itself (Figures 2
and 3) on the condition that cases where there exist probable
inﬂuences of other treatments as docetaxel were excluded.
As shown in Table 1, surgical castration made detectable
serum testosterone in 4 cases undetectable, while in one
casedetectableserumtestosteroneremained detectable(even
increased). In 3 cases, serum testosterone had been already
undetectable with LHRH agonist. The postorchiectomy rate
of cases with serum total testosterone less than 0.05ng/mL
was 87.5% compared with 37.5% before orchiectomy (P =
.039 by the chi-square test). In the case which showed
74% PSA reduction due to surgical castration, presurgical
serum testosterone was 0.07ng/mL, but post-surgical one
was unfortunately unavailable.
Leydig cells were not identiﬁed in excised testes of
hormone-refractory prostate cancer patients by the ordinary
examination of histological specimens.
In patients on LHRH agonist or surgical castration at
leastforthreemonths,theordinarycastrationlevelsofserum
testosterone (<0.5ng/mL and <0.2ng/mL) were achieved
in 98.9% and 93.3%, respectively, by medical castration
and in 98.0% and 96.0% by surgical castration with the
median follow-up period 2.9 years. Serum total testosterone
levels were below the sensitivity threshold (0.05ng/mL)
in 40 of 89 (44.9%) medically castrated patients and 33
of 50 (66.0%) surgically castrated patients as shown in
Figure 1 (not statistically signiﬁcant by the chi-square test;
P = .20). Median serum testosterone levels in patients
(age: 56–78yrs) without experience of androgen deprivation
therapy was 4.02ng/mL (1.61–25.24). Serum testosterone
levels in patients (age: 65–77yrs) who had quitted androgen
deprivation therapy was 0.07–5.50ng/mL (median: 1.49)
with time after cessation of androgen deprivation therapy
0.2–5.1 years.
4.Discussion
Levels of serum total testosterone in prostate cancer patients
on medical and surgical castration were grossly comparable
in this study. Surprisingly, serum testosterone above the
sensitivity threshold was observed even in patients who had
undergone surgical bilateral orchiectomy more than ﬁve
years before. The source of testosterone is basically unknown
in such cases. Extratesticular synthesis of androstenedione
and testosterone was reported to be below 0.2%, but
detected in liver, kidney, and the gastroduodenal tract in
rats [10]. There is possibility that testosterone production
is upregulated in those organs other than testis in patients4 Advances in Urology
who were surgically castrated and show serum testosterone
measurement above the sensitivity threshold. In the clinical
setting, the androgen synthesis in the adrenal gland consist-
ing of 10% ofcirculating androgen ismore important for the
growth of prostate cancer than extratesticular, extra-adrenal
androgen synthesis. Thus, drugs inhibiting adrenal function
such as ketoconazole and corticosteroids are in the clinical
use.
Surgical castration in patients who have been on medical
castration may possibly be more eﬀective in controlling
prostate cancer when castration level caused surgically can
be occasionally more profound than that caused medically.
Actually in this study, one of twelve hormone-refractory
prostate cancer patients with multiple bone metastasis, who
were on LHRH agonist, showed 74% reduction of PSA
following surgical castration. There may be a question if this
case was really hormone refractory or otherwise castration
refractory, because hormone-refractory prostate cancer is
not controlled anymore by hormonal manipulations by
deﬁnition. However, it seems reasonable to classify the case
into hormone refractory as it failed to control cancer with
antiandrogens, estramustine, and corticosteroid. Complete
eradication of testosterone by surgical castration may occa-
sionally be eﬀective even to “hormone-refractory” prostate
cancer. There is a little possibility that ﬂutamide, which was
administered for forty days just before surgical castration
without any eﬀects, accelerated PSA increase, and cessation
of it returned PSA to the preadministration level as shown
in Figure 3. But considering that there was no preceding
administration of ﬂutamide and shortness of the duration
of ﬂutamide prescription, it was not very probable that
there existed mutations in androgen receptor which would
drive cancer growth as ﬂutamide binds to the receptor as an
agonistic ligand.
In reality, changes in serum testosterone levels of those
patients undergoing surgical castration were inconstant, as
some showed decrease with surgical castration while others
not. In some of the latter cases, serum testosterone levels
were already low enough (<0.05ng/mL) with LHRH agonist,
then additional decrease in testosterone might have not been
demonstrable due to the sensitivity of measurement. The
lower threshold of total testosterone measurement is as low
as 0.02ng/mL owing to the recent development of more sen-
sitive assays [11]. If more sensitive total testosterone assays
than that with the lower threshold 0.05ng/mL are used, we
may detect changes in serum total testosterone following
surgical castration more precisely. Otherwise extratesticular
testosteroneproductionmighthaveoccurred asstatedbefore
in a case with considerable remaining serum testosterone
level following surgery.
Standard androgen deprivation by medical castration
does not consistently suppress tumoral androgen activity
and androgen-dependent gene expression in the prostate
microenvironment, leading to adaptive cellular changes
allowing prostate cancer cell survival in a low-androgen
environment [12]. This may support a medical rationale
for indicating surgical castration for prostate cancer patients
resistant to LHRH agonist. Interestingly, there is recently a
paradoxical observation that the growth of some “androgen
sensitive” human prostate cancer cells expressing androgen
receptor can be inhibited by supraphysiologic levels of
androgens [13]. Considering that, there may be cases where
the administration of androgen can paradoxically suppress
prostate cancer which has been treated with androgen
deprivation therapy and ﬁnally converted to “hormone-
refractory” cancer.
Administrating LHRHagonistseveryoneorthreemonth
is costly compared with surgical castration which is not
expensive and requires a hospital stay shorter than a week.
In Japan, surgical fee for bilateral orchiectomy for the
endocrine treatment of prostate cancer is just 27,700 yen,
while 1-monthdepotsofgoserelinand leuprolidecost43,856
and 46,776 yen, respectively, and 3-month depots of those
cost 76,883 and 87,548 yen, respectively. In the time of
economical recession as Japan is suﬀering from, it may be
reasonable to think of giving surgical castration instead of
medical castration to patients with castration-sensitive and
castration-refractory prostate cancer who would hardly quit
androgen deprivation therapy in the course of their illness.
Japan is supposed to be surpassed by China in the Gross
Domestic Product (GDP) by the end of 2010.
5.Conclusion
In conclusion, even hormone-refractory prostate cancer
patients can be candidates for surgical castration because of
endocrinological, oncological, and economical reasons.
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